Clinical Trial Update: Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating third-party allogeneic natural killer cells together with mogamulizumab for relapsed or refractory adult T-cell leukemia/lymphoma and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)
• Third-Party Natural Killer Cells (allogeneic natural killer cells)

Snippet

Sponsor: John Reneau | Conditions: Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING